MedWatch

FDA changes prescribing information for new Alzheimer's drug

Following weeks of criticism of the FDA decision to approve Biogen's Alzheimer's drug Aduhelm, experts within the health authority are narrowing the range of patients that the medicine is recommended for.

Photo: BRIAN SNYDER/REUTERS / X90051

Just one month after the US Food and Drug Administration (FDA) vouched for Biogen's drug Aduhelm for treating Alzheimer's disease, the authority has adjusted the prescribing information for this medication, which changes the patients that the drug should be recommended to.

Biogen took the initiative to this drug on the basis of conversations, which Biogen representatives have had with doctors after the approval.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs